A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 6, 2019

Primary Completion Date

June 26, 2020

Study Completion Date

July 15, 2020

Conditions
NAFLDNASH
Interventions
DRUG

Elobixibat

Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).

DRUG

Placebo oral tablet

Placebo identical in appearance to active drug

Trial Locations (10)

21202

Mercy Medical Center, Baltimore

23298

Virginia Commonwealth University, Richmond

33166

Integrity Clinical Research, LLC, Doral

33614

Guardian Angel Research Center, Inc., Tampa

34452

Nature Coast Clinical Research, Inverness

78215

American Research Corporation at the Texas Liver Institute, San Antonio

80907

Peak Gastroenterology Associates, Colorado Springs

91303

Hope Clinical Research, Canoga Park

92377

Inland Empire Clinical Trials, LLC, Rialto

98195

University of Washington, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Albireo

INDUSTRY

NCT04006145 - A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH | Biotech Hunter | Biotech Hunter